2X Blend CJC-1295/Ipamorelin
2X Blend CJC-1295/Ipamorelin
Blend - CJC-1295 (29aa modified) and Ipamorelin (5aa)
Overview
The 2X CJC-1295/Ipamorelin blend combines two complementary growth hormone secretagogue pathways into a single formulation. CJC-1295 (Modified GRF 1-29) targets the GHRH receptor on pituitary somatotrophs, activating the Gs-cAMP-PKA signaling cascade to promote GH synthesis and release. Ipamorelin targets the ghrelin receptor (GHS-R1a), triggering GH release through phospholipase C-mediated calcium mobilization. The scientific rationale for this combination is well-established. Research dating to the 1980s by Bowers and colleagues demonstrated that simultaneous stimulation of the GHRH pathway and the ghrelin/GHRP pathway produces GH release that is synergistic — meaning the combined output significantly exceeds the mathematical sum of individual responses. This synergy occurs because the two pathways converge on pituitary somatotrophs through different intracellular signaling mechanisms (cAMP for GHRH; calcium/IP3 for ghrelin), and their simultaneous activation produces a multiplicative rather than additive effect. Ipamorelin was selected for this blend due to its selectivity — it stimulates GH without significantly affecting cortisol, prolactin, or ACTH at GH-releasing doses. This clean secretagogue profile, combined with CJC-1295's GHRH-receptor activity, produces a targeted GH stimulus with minimal off-target endocrine effects.
Mechanism of Action
The 2X CJC-1295/Ipamorelin blend combines two complementary growth hormone secretagogue pathways into a single formulation. CJC-1295 (Modified GRF 1-29) targets the GHRH receptor on pituitary somatotrophs, activating the Gs-cAMP-PKA signaling cascade to promote GH synthesis and release. Ipamorelin targets the ghrelin receptor (GHS-R1a), triggering GH release through phospholipase C-mediated calcium mobilization. The scientific rationale for this combination is well-established. Research dating to the 1980s by Bowers and colleagues demonstrated that simultaneous stimulation of the GHRH pathway and the ghrelin/GHRP pathway produces GH release that is synergistic — meaning the combined output significantly exceeds the mathematical sum of individual responses. This synergy occurs because the two pathways converge on pituitary somatotrophs through different intracellular signaling mechanisms (cAMP for GHRH; calcium/IP3 for ghrelin), and their simultaneous activation produces a multiplicative rather than additive effect. Ipamorelin was selected for this blend due to its selectivity — it stimulates GH without significantly affecting cortisol, prolactin, or ACTH at GH-releasing doses. This clean secretagogue profile, combined with CJC-1295's GHRH-receptor activity, produces a targeted GH stimulus with minimal off-target endocrine effects.
Key Research Findings
- Bowers et al. (1984) established the synergistic relationship between GHRH and GHRP pathways, the foundational science behind CJC-1295/ipamorelin combinations.
- Teichman et al. (2006) demonstrated CJC-1295 produces sustained GH and IGF-1 elevation in healthy adults.
- Raun et al. (1998) showed ipamorelin is the first fully selective GH secretagogue, releasing GH without affecting cortisol or prolactin.
- Veldhuis et al. (2012) reviewed GH secretagogue synergy and its implications for age-related GH decline.
Citations & References
On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone
Bowers CY, Momany FA, Reynolds GA, Hong A. — Endocrinology (1984)
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295
Teichman SL, Neale A, Lawrence B, et al. — J Clin Endocrinol Metab (2006)
Ipamorelin, the first selective growth hormone secretagogue
Raun K, Hansen BS, Johansen NL, et al. — Eur J Endocrinol (1998)
Dosage in Research
Research references individual component dosing. CJC-1295: 15-60 mcg/kg SC. Ipamorelin: 0.1-1 mg/kg. Combination protocols administer both simultaneously.
Dosage information is derived from published research literature and is presented for educational purposes only. This is not medical advice. All products are for laboratory research use only.
Storage & Handling
Store lyophilized (freeze-dried) powder at -20°C to 4°C in a dry environment protected from light. Unreconstituted peptide is stable for extended periods when stored properly.
Once reconstituted with bacteriostatic water or an appropriate solvent, store at 2-8°C and use within the timeframe specified on the Certificate of Analysis. Avoid repeated freeze-thaw cycles.
A Certificate of Analysis documenting purity, identity, and recommended storage conditions is included with every order.
Frequently Asked Questions
What is 2X Blend CJC-1295/Ipamorelin?
What purity is your 2X Blend CJC-1295/Ipamorelin?
How should I store 2X Blend CJC-1295/Ipamorelin?
Is 2X Blend CJC-1295/Ipamorelin for human use?
Where can I buy 2X Blend CJC-1295/Ipamorelin?
Research Use Only
All products are intended for laboratory research and educational purposes only. Products have not been evaluated by the FDA and are not intended for human consumption, diagnosis, treatment, or prevention of any disease. Purchasers must be 21+ and confirm research use intent.